Samjin Pharmaceutical Appoints Executive Director Lee Soo-min as Head of Magok Research Center

Sumin Lee, Head of Samjin Pharmaceutical Magok Research Center.

[Asia Economy Reporter Lee Gwan-joo] Samjin Pharmaceutical announced on the 31st that it has recruited Lee Soo-min, former head of the Open Innovation Team at SK Chemicals, as the Director of the Magok Research Center (Executive Director).

Director Lee is an R&D expert who earned a bachelor's degree in Animal Science and a master's degree in Molecular Biology from Seoul National University, and a Ph.D. in Pharmacology and Toxicology from the University of California Irvine. He joined SK Chemicals R&D Center as a researcher in 2004 and has been responsible for new drug development, AI platform development, joint research, and investment management. Recently, he led the SK Chemicals Open Innovation Team established in 2019, playing a pivotal role in efficient innovative drug development by signing partnership agreements with various AI drug development companies and bio ventures.

With the recruitment of Director Lee, Samjin Pharmaceutical plans to make every effort to achieve tangible R&D results. The Magok Research Center, completed in December last year with a total investment of 40 billion KRW, is equipped with state-of-the-art facilities and R&D infrastructure. Currently, innovative therapeutic research is underway targeting diseases with high unmet medical needs such as cancer, fibrotic diseases, ophthalmic diseases, degenerative brain diseases, and autoimmune diseases. Director Lee is expected to play a significant role in innovative drug development through open innovation with domestic and international research institutions and pharmaceutical bio companies.

Director Lee said, "I feel a heavy responsibility in taking on the important role of leading Samjin Pharmaceutical’s Magok era research center, and I will strive to quickly achieve results in internal new drug projects," adding, "I will initiate new R&D projects and strengthen mid- to long-term R&D capabilities to ensure that Samjin Pharmaceutical can leap forward as a specialized new drug development pharmaceutical company."

This content was produced with the assistance of AI translation services.